Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Sotigalimab (DHD68911)

Host species:Humanized
Isotype:IgG1-Kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHD68911

Description

The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-Kappa

Clonality

Monoclonal

Target

Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Concentration

1.7 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P25942

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6

Clone ID

Sotigalimab

Data Image
  • SDS-PAGE
    SDS PAGE for Sotigalimab
  • Bioactivity
    Detects CD40/TNFRSF5 in indirect ELISAs.
References

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study, PMID: 33387490

A CD40 Agonistic Antibody Shows Signs of Efficacy in Pancreatic Cancer, PMID: 33451984

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1, PMID: 34140403

Datasheet

Document Download

Research Grade Sotigalimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Sotigalimab [DHD68911]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only